The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Open accessAbstract
BACKGROUND: Higher intake of marine n-3 (also called omega-3) fatty acids has been associated with reduced risks of cardiovascular disease and cancer in several observational studies. Whether supplementation with n-3 fatty acids has such effects in general populations at usual risk for these end points is unclear. METHODS: (at a dose of 2000 IU per day) and marine n-3 fatty acids (at a dose of 1 g per day) in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States. Primary end points were major cardiovascular events (a composite of myocardial infarction, stroke, or death from cardiovascular causes) and invasive cancer of any type. Secondary end points included individual components of the composite cardiovascular end point, the composite end point plus coronary revascularization (expanded composite of cardiovascular events), site-specific cancers, and death from cancer. Safety was also assessed. This article reports the results of the comparison of n-3 fatty acids with placebo. RESULTS: A total of 25,871 participants, including 5106 black participants, underwent randomization. During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24). Invasive cancer was diagnosed in 820 participants in the n-3 group and in 797 in the placebo group (hazard ratio, 1.03; 95% CI, 0.93 to 1.13; P=0.56). In the analyses of key secondary end points, the hazard ratios were as follows: for the expanded composite end point of cardiovascular events, 0.93 (95% CI, 0.82 to 1.04); for total myocardial infarction, 0.72 (95% CI, 0.59 to 0.90); for total stroke, 1.04 (95% CI, 0.83 to 1.31); for death from cardiovascular causes, 0.96 (95% CI, 0.76 to 1.21); and for death from cancer (341 deaths from cancer), 0.97 (95% CI, 0.79 to 1.20). In the analysis of death from any cause (978 deaths overall), the hazard ratio was 1.02 (95% CI, 0.90 to 1.15). No excess risks of bleeding or other serious adverse events were observed. CONCLUSIONS: Supplementation with n-3 fatty acids did not result in a lower incidence of major cardiovascular events or cancer than placebo. (Funded by the National Institutes of Health and others; VITAL ClinicalTrials.gov number, NCT01169259 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“although only REDUCE-IT has shown cardiovascular benefits (as discussed later) (14-17).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“butseverallargeclinicaltrialsfailed to demonstrate any cardiovascular benefit with administration of low doses of omega-3 fatty acids. 8,12,13”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TheVitaminDandOmega-3Trial(VITAL), in which 13% of the participants had type 2 diabetes, supplementation with 1 g of omega-3 fatty acids did not result in a lower incidence of major cardiovascular events (305).”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [305]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials revealed that ω3 PUFA supplementation of <1 g/d resulted in a very limited reduction in atherosclerotic CVD risk of major vascular events and CVD‐caused deaths. 22 , 23 , 133 , 154”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [23]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies showed inconsistent reductions in MACE.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple large studies conducted since then to examine the benefits of low-dose mixtures of EPA and DHA with more contemporary background therapy, including statin therapy, have failed to show any significant reduction in cardiovascular endpoints.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, other recent trials studying lower doses of omega-3 fatty acids in a broader range of patients failed to demonstrate significant reductions of total cardiovascular events. 12,13”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“This may explain why EPA + DHA combination treatment in various trials did not demonstrate an effect on reducing cardiovascular risk. 23 , 24 , 25 , 133”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Earlier trials such as GISSI-Prevenzione, ASCEND, VITAL, and OMEMI evaluated low-dose EPA/DHA mixtures primarily in primary prevention settings or post-MI patients, often without significant baseline TG elevation and with limited use of statins in earlier trials [87–90].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ASCEND (A Study of Cardiovascular Events in Diabetes) [3] and VITAL (Vitamin D and Omega-3 Trial) trials [5] using EPA+DHA did not signi fi cantly reduce the primary cardiovascular endpoints”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“During a median follow-up of 5.3 years, there was no significant difference in the 2 primary endpoints of major cardiovascular events (a composite of MI, stroke, or death from cardiovascular causes) or invasive cancer of any type.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
In the citing paper
“Contemporary studies were conducted with higher standards and consistently failed to demonstrate significant benefits.”
In the citing paper
“at lower doses (1 g/day) these agents have generally failed to show reduced ASCVD.50,51”
From Clinical review on triglycerides (2020) · cites this paper as [51]
In the citing paper
“Recently, a new selective PPAR-α modulator (pemafibrate) has been reported to have marked efficacy in reducing TRLs [317].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [317]
In the citing paper
“However, this trial showed that just 840 mg of combined EPA/DHA significantly reduced MI and major CHD events [63].”
From Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health (2022) · cites this paper as [63]
In the citing paper
“This study did not show that supplementing with n-3 fatty acids reduced the incidence of major CVD events (a composite of MI, stroke, and death from CVD causes) or invasive cancer.”
From Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health (2022) · cites this paper as [63]
In the citing paper
“Individuals with low baseline fish consumption (<1.5 servings/week) had decreased risk for total CV events (hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.67 to 0.98).”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“However, there was a 28% reduction in total MI, which emerged after the first year and continued throughout the trial.”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“In the VITAL trial, omega-3 PUFAs did not significantly reduce the primary composite endpoint of major ASCVD events (MI, stroke, and CVD mortality).”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“Black study participants experienced a 77% treatment-associated reduction in MI (HR: 0.23; 95% CI: 0.11 to 0.47), and derived an MI benefit irrespective of baseline fish intake.”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“There were significant reductions in other pre-specified secondary outcomes, including a 17% reduced risk for total coronary heart disease (CHD) and a 50% reduction in fatal MI”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“In the statin era, CVOTs of combination OM-3 fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] have not shown reduction in cardiovascular disease (CVD) events.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“Additional factors that may influence CVOT findings include OM-3 dose, definition of primary composite CV endpoint, and study population.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“The total daily dose of OM-3 was much lower in VITAL and ASCEND (< 1 g/day total OM-3 per each 1-g capsule) than in REDUCE-IT (4 g/day high-purity Rx EPA).”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“The primary composite CV endpoint varied between the studies (Table 1, see footnote); for example, in REDUCE-IT, coronary revascularization and unstable angina were included, in addition to CV death, nonfatal myocardial infarction, and nonfatal stroke.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“A 17% risk reduction was recorded for total coronary heart disease, versus placebo.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“Indeed, while the primary outcome of the study, a reduction in major cardiovascular events (a composite of myocardial infarction, stroke, and death from cardiovascular causes), was not achieved with statistical significance, the analysis did demonstrate an 8% reduction in such events.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“Interestingly for African-Americans, the study found a dramatic 77% reduction in heart attacks linked to daily omega-3 supplementation.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“In people who do not consume the recommended 1 or 2 servings of fish a week, the n-3 LCPUFA supplementation was linked to a 40% reduction in heart attacks; however, among the subjects who followed the fish consumption recommendation, there was no such association.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“The primary conclusion of the VITAL study was not positive regarding the effect of supplementation with n-3 LCPUFA on major cardiovascular events as the data failed to show a lower incidence of major cardiovascular events in the experimental group than in the placebo control group [53].”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“However, the secondary outcomes were highly relevant as omega-3 supplementation was associated with a reduction in total and fatal myocardial infarction risk by 28% and 50%, respectively.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,350
Self-citationPrevalence of Overweight and Obesity in the United States, 1999-2004
Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. (2006) · JAMA · doi:10.1001/jama.295.13.1549 · Cited by 8,720
Third universal definition of myocardial infarction
the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., CHAITMAN, B. R., & White, H. D. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.122 · Cited by 6,585
Isolated Hand Paresis: A Case Series
Alstadhaug, K. B., & Sjulstad, A. S. (2013) · Cerebrovascular Diseases Extra · doi:10.1159/000350708 · Cited by 4,090
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 984
Liu, S., Faitg, J., Tissot, C., Konstantopoulos, D., Laws, R., Bourdier, G., Andreux, P. A., Davey, T., Gallart‐Ayala, H., Ivanišević, J., et al. (2025) · iScience · doi:10.1016/j.isci.2025.111814 · Cited by 39
Polyunsaturated fatty acids and sepsis
Das, U. N. (2019) · Nutrition · doi:10.1016/j.nut.2019.02.016 · Cited by 30
Vitamin D and Vascular Disease
Gouni‐Berthold, I., & Berthold, H. K. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118666200317151955 · Cited by 31
Larsson, S. C., Carter, P., Vithayathil, M. K., Mason, A. M., Michaëlsson, K., Baron, J. A., & Burgess, S. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.11.004 · Cited by 30
“Randomized controlled trials of n-3 fatty acid supplementation (EPA and DHA) yielded negative results, but did show some non-signi fi cant, modest increases in risk [27,28].”
InfluentialTreating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 32
Effects of Vitamin D3 Supplementation on Body Composition in the VITamin D and OmegA-3 TriaL (VITAL)
Chou, S. H.-H., Murata, E. M., Yu, C., Danik, J. S., Kotler, G., Cook, N. R., Bubes, V. Y., Mora, S., Chandler, P. D., Tobias, D. K., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa981 · Cited by 30
Self-citationMental Health in Childhood and Adolescence: The Role of Polyunsaturated Fatty Acids
Bozzatello, P., Blua, C., Rocca, P., & Bellino, S. (2021) · Biomedicines · doi:10.3390/biomedicines9080850 · Cited by 30
“Among n-3-PUFAs, the forms relevant for human health are α-linolenic acid (ALA, C18:3n-3), eicosapentaenoic acid (EPA, C20:5n-3), and docosahexaenoic acid (DHA, C22:6n-3), whereas among the n-6 family, there are linoleic acid (LA, C18:2n-6), di homo-γ-linolenic acid (DGLA, 20:3n-6), and arachidonic acid (AA, C20:4n6)…”
BackgroundOmega‐3 fatty acids for the prevention of atherosclerotic cardiovascular disease
Barry, A. R., & Dixon, D. L. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2615 · Cited by 31
Zelniker, T. A., Morrow, D. A., Scirica, B. M., Furtado, J. D., Guo, J., Mozaffarian, D., Sabatine, M. S., & O’Donoghue, M. L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.017401 · Cited by 26
Omega-3 PUFAs slow organ aging through promoting energy metabolism
Xiong, Y., Li, X., Liu, J., Luo, P., Zhang, H., Zhou, H., Ling, X., Zhang, M., Ye, L., Chen, Q., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107384 · Cited by 30
Omega-3 Polyunsaturated Fatty Acids and Stroke Burden
Ueno, Y., Miyamoto, N., Yamashiro, K., Tanaka, R., & Hattori, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225549 · Cited by 30
“997) (d) Reference number [44] [51,52] [45,46] [48] [47] [50] [49] [53,54]”
Dong, Y., Zhu, H., Chen, L., Huang, Y., Christen, W. G., Cook, N. R., Copeland, T., Mora, S., Buring, J. E., Lee, I.-M. M., et al. (2022) · Nutrients · doi:10.3390/nu14245307 · Cited by 33
“men and women, aged ≥50 and ≥55, respectively [26,27].”
BackgroundSelf-citationSea Change for Marine Omega-3s
O'Keefe, E. L., Harris, W. S., DiNicolantonio, J. J., Elagizi, A., Milani, R. V., Lavie, C. J., & O'Keefe, J. H. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.04.027 · Cited by 28
Kurek, M., Ščetar, M., Nuskol, M., Janči, T., Tanksoić, M., Klepac, D., Semenčić, M. Č., & Galić, K. (2024) · Antioxidants · doi:10.3390/antiox13060707 · Cited by 28
“Regular consumption of fish oil has been linked to numerous health benefits, including lowering the risk of heart disease, improving mental health, and aiding in the management of inflammatory conditions such as arthritis [30,31].”
BackgroundThe role of biofactors in the prevention and treatment of age‐related diseases
Frank, J., Kisters, K., Stirban, O. A., Obeid, R., Lorkowski, S., Wallert, M., Egert, S., Podszun, M. C., Eckert, G. P., Pettersen, J. A., et al. (2021) · BioFactors · doi:10.1002/biof.1728 · Cited by 28
“3 years.(81) These results are in line with the conclusions from previously published studies.”
ResultEffectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia
Mozaffarian, D., Maki, K. C., Bays, H. E., Aguilera, F., Gould, G., Hegele, R. A., Moriarty, P. M., Robinson, J. G., Shi, P., Tur, J. F., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.41898 · Cited by 30
Bäck, M., Xhaard, C., Rouget, R., Thuillier, Q., Plunde, O., Larsson, S. C., Girerd, N., Ferreira, J. P., Boivin, J., Bozec, E., et al. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac016 · Cited by 27
“9 In addition, cardiovascular risk reduction by omega-3 PUFA supplementation is more pronounced in subjects with low basal dietary omega-3 PUFA intake, 6 supporting that the overall omega-3 PUFA exposure is of importance for cardiovascular health.”
BackgroundBioactive Lipids: Chemistry & Health Benefits
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac106.66766687 · Cited by 27
“consumption of 1 g omega-3 fatty acid daily led to a significant reduction in the cumulative rate of all-cause death [27].”
BackgroundOmega-3 and cardiovascular prevention – Is this still a choice?
Ruscica, M., Sirtori, C. R., Carugo, S., Calder, P. C., & Corsini, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106342 · Cited by 29
Hao, J., Jin, R., Zeng, J., Hua, Y., Yorek, M. S., Liu, L., Mandal, A., Li, J., Zheng, H., Sun, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111804 · Cited by 25
“8 Thus, the adverse effects of n-3 FAs on hair growth may be underestimated at these low consumption levels.”
Maina, A. N., Lewis, E., & Kiarie, E. G. (2023) · Poultry Science · doi:10.1016/j.psj.2023.102921 · Cited by 27
Dicklin, M. R., Anthony, J. C., Winters, B., & Maki, K. C. (2024) · Journal of Nutrition · doi:10.1016/j.tjnut.2024.03.015 · Cited by 32
Amigó, N., Akinkuolie, A. O., Chiuve, S. E., Correig, X., Cook, N. R., & Mora, S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014963 · Cited by 29
“Although some randomized trials and subsequent metaanalyses have questioned the value of n-3 fatty acid supplementation in CVD risk reduction,(4) 2 recent clinical trials—VITAL (Vitamin D and Omega-3 Trial) and REDUCE IT (Reduction of Cardiovascular Events with Icosapent EthylIntervention)—found cardiovascular benefit…”
ResultSelf-citationVITAL Signs for Dietary Supplementation to Prevent Cancer and Heart Disease
Keaney, J. F., & Rosen, C. J. (2018) · New England Journal of Medicine · doi:10.1056/nejme1814933 · Cited by 28
Fravel, M. A., Ernst, M. E., Gilmartin‐Thomas, J., Woods, R. L., Orchard, S. G., Owen, A. J., & the ASPirin in Reducing Events in the Elderly Investigator Group (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18305 · Cited by 26
New approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26
Dealing with saturated and unsaturated fatty acid metabolism for anticancer therapy
Dierge, E., & Féron, O. (2019) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000601 · Cited by 25
Could Omega 3 Fatty Acids Preserve Muscle Health in Rheumatoid Arthritis?
Lanchais, K., Capel, F., & Tournadre, A. (2020) · Nutrients · doi:10.3390/nu12010223 · Cited by 25
Metherel, A. H., Irfan, M., Klingel, S. L., Mutch, D. M., & Bazinet, R. P. (2020) · Lipids · doi:10.1002/lipd.12291 · Cited by 28
Zhuang, P., Liu, X., Li, Y., Wu, Y., Li, H., Wan, X., Zhang, L., Xu, C., Jiao, J., & Zhang, Y. (2023) · Science Advances · doi:10.1126/sciadv.adf9037 · Cited by 26
Bowman, G. L., Silbert, L. C., Dodge, H. H., Lahna, D. L., Hagen, K., Murchison, C., Howieson, D. B., Kaye, J. A., Quinn, J. F., & Shinto, L. H. (2019) · Nutrients · doi:10.3390/nu11040735 · Cited by 26
“These include well-established effects on vascular health, leading to recommendations for a standard of care in primary and secondary prevention of coronary heart disease [32], refined further based on more recent clinical trial data [15,33].”
Backgroundon behalf of the ISACA guideline working group, De Crescenzo, F., D’Alò, G. L., Morgano, G. P., Minozzi, S., Mitrova, Z., Saulle, R., Cruciani, F., Fulceri, F., Davoli, M., et al. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01284-5 · Cited by 52
Yuan, T., Si, S., Li, Y., Li, W., Chen, X., Liu, C., Li, J., Wang, B., Hou, L., Liu, Y., et al. (2020) · Nutrition Journal · doi:10.1186/s12937-020-00582-4 · Cited by 26
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 25
“taining 460 mg of EPA and 380 mg of docosahexaenoic acid (DHA) showed no significant effect on the incidence of major cardiovascular events or cancer compared to placebo [94].”
BackgroundDurstenfeld, M. S., & Hsue, P. Y. (2021) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000681 · Cited by 26
Petersen, K. S., Kris‐Etherton, P. M., McCabe, G. P., Raman, G., Miller, J. W., & Maki, K. C. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab045 · Cited by 26
“1618 Petersen et al. In the case of VITAL (29), the results for cardiacrelated secondary outcomes did not show unequivocal evidence of benefit after consideration of the number of statistical comparisons.”
BackgroundInfluentialThe Role of Micronutrients in Ageing Asia: What Can Be Implemented with the Existing Insights
Inui, T., Hanley, B., Tee, E. S., Nishihira, J., Tontisirin, K., Dael, P. V., & Eggersdorfer, M. L. (2021) · Nutrients · doi:10.3390/nu13072222 · Cited by 25
“The study reported a statistically significant reduction in coronary heart disease in the omega-3 arm (17% risk reduction) [79].”
BackgroundDyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 26
“The Vitamin D and Omega-3 Trial (VITAL) trial showed that n-3 fatty acids did not result in a lower incidence of major CV events than placebo after a median follow-up of 5.3 years (HR 0.92; 95% CI 0.80 to 1.06; p = 0.24) [104].”
BackgroundInfluentialCardiovascular Risk Reduction with Icosapent Ethyl
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1902165 · Cited by 24
Omega-3 Fatty Acids and Arrhythmias
Marcus, M. D., & Link, M. S. (2024) · Circulation · doi:10.1161/circulationaha.123.065769 · Cited by 30
Lewis, E., Steenson, S., Haslam, R. P., McDonald, E., Sharman, M., Τράκα, Μ., Stanton, A. V., Napier, J. A., Sweeting, A., Saleh, R. N. M., et al. (2025) · Nutrition Research Reviews · doi:10.1017/s0954422425100127 · Cited by 30
The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future
Perez-Martinez, P., Katsiki, N., & Mikhailidis, D. P. (2019) · Angiology · doi:10.1177/0003319719842005 · Cited by 24
“However, subgroup analyses showed that n-3 fatty acids supplementation led to significant CVD benefits in those with lower dietary fish intake, in African Americans, and those with comorbidities.(12) Of note, there is no information regarding fasting status of lipid measurements in this trial.”
ResultThe Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
Wang, X., Verma, S., Mason, R. P., & Bhatt, D. L. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01343-7 · Cited by 24
Non‐genetic biomarkers and colorectal cancer risk: Umbrella review and evidence triangulation
Zhang, X., Gill, D., He, Y., Yang, T., Li, X., Monori, G., Campbell, H. J., Dunlop, M. G., Tsilidis, K. K., Timofeeva, M. N., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3051 · Cited by 22
Boden, W. E., Baum, S. J., Toth, P. P., Fazio, S., & Bhatt, D. L. (2020) · Future Cardiology · doi:10.2217/fca-2020-0106 · Cited by 23
The VITamin D and OmegA-3 TriaL (VITAL): Do Results Differ by Sex or Race/Ethnicity?
Bassuk, S. S., Chandler, P. D., Buring, J. E., & Manson, J. E. (2020) · American Journal of Lifestyle Medicine · doi:10.1177/1559827620972035 · Cited by 22
Self-citationStivala, S., Gobbato, S., Bonetti, N. R., Camici, G. G., Lüscher, T. F., & Beer, J. H. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15581 · Cited by 23
Ma, T., He, L., Luo, Y., Li, J., Zhang, G., Cheng, X., & Bai, Y. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-02889-w · Cited by 23
Miller, M. J., Tokgözoğlu, L. S., Parhofer, K. G., Handelsman, Y., Leiter, L. A., Landmesser, U., Brinton, E. A., & Catapano, A. L. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2103541 · Cited by 25
Yu, F., Qi, S., Ji, Y., Wang, X., Fang, S., & Cao, R. (2022) · Medicine · doi:10.1097/md.0000000000029556 · Cited by 23
Dietary supplements and bleeding
Hatfield, J., Saad, S. S., & HOUSEWRIGHT, C. D. (2022) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2022.2121575 · Cited by 23
“Finally, a large RCT involving 25,871 participants showed no excess risks of bleeding associated with fish oil.(42) As with fish oil, there are many case reports of the various types of ginseng associated with bleeding events and procoagulation events.”
BackgroundDietary chia (Salvia hispanica L.) improves the nutritional quality of broiler meat
Nardelli, N. B. D. S., Filho, S. T. S., de Oliveira, D. H., Lima, E. M. C., Rosa, P. V., Faria, P. B., Naves, L. D. P., & Rodrigues, P. B. (2019) · Asian-Australasian Journal of Animal Sciences · doi:10.5713/ajas.19.0608 · Cited by 23
“Human food, enriched with ω-3 PUFA, has gained increasing attention from the consumer market due to the increasingly widespread knowledge of the beneficial effects of these compounds in the promotion of cardiovascular health and even in the prevention and treatment of inflammatory and autoimmune diseases and cancer [3…”
BackgroundMohamed, D., Mohammed, S., & Hamed, I. (2021) · Journal of Herbmed Pharmacology · doi:10.34172/jhp.2022.09 · Cited by 22
“Omega-3 fatty acids supplementation exhibited beneficial activities in preventing CVD through lipid lowering, inflammation, and oxidative stress (reduced reactive oxygen species) (48).”
BackgroundTong, J., Wang, Z., Zhang, J., Gao, R., Liu, X., Liao, Y., Guo, X., & Wei, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c13607 · Cited by 22
Zhu, H., Manson, J. E., Cook, N. R., Bekele, B. B., Chen, L., Kane, K., Huang, Y., Li, W., Christen, W., Lee, I.-M. M., et al. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.05.003 · Cited by 28
Self-citationPenson, P. E., & Banach, M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00887-z · Cited by 23
Dietary supplements in the USA: problematic trends
Denham, B. E. (2021) · Public Health Nutrition · doi:10.1017/s1368980021000665 · Cited by 22
Sepidarkish, M., Rezamand, G., Qorbani, M., Heydari, H., Estêvão, M. D., Omran, D., Morvaridzadeh, M., Roffey, D. M., Farsi, F., Ebrahimi, S., et al. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1915743 · Cited by 23
Yang, B., Tseng, P., Hu, X., Zeng, B., Chang, J. P., Liu, Y., Chu, W.-J., Zhang, S., Zhou, Z.-L., Chu, C., et al. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101196 · Cited by 23
Fat and fatty acids – a scoping review for Nordic Nutrition Recommendations 2023
Retterstøl, K., & Rosqvist, F. (2024) · Food & Nutrition Research · doi:10.29219/fnr.v68.9980 · Cited by 26
Omega-3 Long-chain Polyunsaturated Fatty Acids for Bronchopulmonary Dysplasia: A Meta-analysis
Wang, Q., Zhou, B., Cui, Q., & Chen, C. (2019) · PEDIATRICS · doi:10.1542/peds.2019-0181 · Cited by 21
“with omega-3 fatty acids did not result in a lower incidence of major cardiovascular events compared with a placebo.(69) A meta-analysis demonstrated that omega-3 fatty acids had no significant association with fatal or nonfatal coronary heart disease or any major vascular events and provided no supporting evidence fo…”
ResultGenomics of hypertriglyceridemia
Tada, H., Takamura, M., & Kawashiri, M. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.12.005 · Cited by 22
Clinical significance of polyunsaturated fatty acids in the prevention of cardiovascular diseases
Kotlyarov, S. N., & Котлярова, А. А. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.998291 · Cited by 22
Review of recent clinical trials and their impact on the treatment of hypercholesterolemia
Parham, J. S., & Goldberg, A. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.011 · Cited by 22
Characteristics, Physiopathology and Management of Dyslipidemias in Pregnancy: A Narrative Review
Formisano, E., Proietti, E., Perrone, G., Demarco, V., Galoppi, P., Stefanutti, C., & Pisciotta, L. (2024) · Nutrients · doi:10.3390/nu16172927 · Cited by 23
Busa, V., Dardeir, A., Marudhai, S., Patel, M., Subas, S. V., Ghani, M. R., & Cancarevic, I. (2020) · Cureus · doi:10.7759/cureus.10840 · Cited by 24
“Results from the current literature have shown a wide range of variations and inconsistencies [14-19].”
BackgroundBardová, K., Funda, J., Pohl, R., Čajka, T., Hensler, M., Kuda, O., Janovská, P., Adamcová, K., Irodenko, I., Lenkova, L., et al. (2020) · Nutrients · doi:10.3390/nu12123737 · Cited by 24
Do omega-3 fatty acids benefit health?
Curfman, G. (2020) · JAMA · doi:10.1001/jama.2020.22898 · Cited by 20
Regulatory Compliance of Health Claims on Omega-3 Fatty Acid Food Supplements
Fuentes, J. B., Beara, I. N., & Torović, L. D. (2024) · Foods · doi:10.3390/foods14010067 · Cited by 23
“This study found no significant benefit of ω -3-FA supplementation in reducing cardiovascular events or cancer incidence [22].”
Demler, O., Liu, Y., Luttmann‐Gibson, H., Watrous, J. D., Lagerborg, K. A., Dashti, H., Giulianini, F., Heath, M., Camargo, C. A., Harris, W. S., et al. (2020) · Metabolites · doi:10.3390/metabo10110431 · Cited by 20
“In particular, myocardial infarction (MI) was decreased by 28% [4,5].”
BackgroundSelf-citationEffect of vitamin D and/or omega‐3 fatty acid supplementation on stroke outcomes: A randomized trial
Rist, P. M., Buring, J. E., Cook, N. R., Manson, J. E., & Rexrode, K. M. (2020) · European Journal of Neurology · doi:10.1111/ene.14623 · Cited by 20
“The main results of the trial are reported elsewhere [2,3].”
BackgroundResultSelf-citationSun, Q., Xin, X., An, Z., Hu, Y., & Feng, Q. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.854879 · Cited by 20
Djoussé, L., Cook, N. R., Kim, E., Walter, J. N., Al-Ramady, O. T., Luttmann‐Gibson, H., Albert, C. M., Mora, S., Buring, J. E., Gaziano, J. M., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2021.12.006 · Cited by 21
Self-citationHealth Claims and Doses of Fish Oil Supplements in the US
Assadourian, J. N., Peterson, E. D., McDonald, S., Gupta, A., & Návar, A. M. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.2424 · Cited by 22
Grant, J. K., Dangl, M. D., Ndumele, C. E., Michos, E. D., & Martin, S. S. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100493 · Cited by 25
Omega-3 fatty acids in primary and secondary prevention of cardiovascular diseases
Tutor, A. W., O’Keefe, E. L., Lavie, C. J., Elagizi, A., Milani, R. V., & O’Keefe, J. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.03.009 · Cited by 25
Lipoprotection in cardiovascular diseases
Benkhoff, M., & Polzin, A. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108747 · Cited by 20
Allaire, J., Vors, C., Harris, W. S., Jackson, K. H., Tchernof, A., Couture, P., & Lamarche, B. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519000552 · Cited by 20
Fish Oil and Cardiometabolic Diseases: Recent Updates and Controversies
Tummala, R., Ghosh, R. K., Jain, V., Devanabanda, A. R., Bandyopadhyay, D., DEEDWANIA, P. C., & Aronow, W. S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.04.027 · Cited by 21
Park, I., Xun, P., Tsinovoi, C. L., Klemmer, P. J., Liu, K., & He, K. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-02022-4 · Cited by 20
Trivedi, K., Le, V. T., & Nelson, J. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1783937 · Cited by 20
Dietary phytochemicals alleviate the premature skin aging: A comprehensive review
Singh, H., Kamal, Y. T., Pandohee, J., Mishra, A. K., Biswas, A., Mohanto, S., Kumar, A., Nag, S., Mishra, A., Singh, M., et al. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112660 · Cited by 30
Vitamin D’s Impact on Cancer Incidence and Mortality: A Systematic Review
Wimalawansa, S. J. (2025) · Nutrients · doi:10.3390/nu17142333 · Cited by 19
“Like the WHI [151] and VITAL study [45,324], several other large, mega RCTs enrolled vitamin D-sufficient subjects and allowed participants to consume over-the-counter supplements [47], including vitamin D [47,53].”
InfluentialHu, T., Zhang, W., Han, F., Zhao, R., Liu, L., & An, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903412 · Cited by 20
“Numerous epidemiological and clinical studies showed that the supplementation of n-3 PUFAs is associated with decreased inflammation (32, 33).”
Backgroundn-3 Fatty acids and risk for fatal coronary disease
Harris, W. S., & Zotor, F. B. (2019) · Proceedings of The Nutrition Society · doi:10.1017/s0029665118002902 · Cited by 19
Kim, J. S., Steffen, B. T., Podolanczuk, A. J., Kawut, S. M., Noth, I., Raghu, G., Michos, E. D., Hoffman, E. A., Axelsson, G. T., Guðmundsson, G., et al. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa168 · Cited by 17
Dietary Omega-3 Fatty Acid Intake and Mortality in CKD Population: A 1999–2014 NHANES Analysis
Li, W.-L., Zhang, N.-H., Ge, S.-W., & Xu, G. (2021) · American Journal of Nephrology · doi:10.1159/000520027 · Cited by 16
Gill, R., Al‐Badr, M., Al-Ghouti, M. A., Mohamed, N. A., Abou-Saleh, H., & Rahman, M. M. (2024) · Marine Drugs · doi:10.3390/md22060256 · Cited by 19
Grytten, E., Laupsa‐Borge, J., Cetin, K., Bohov, P., Nordrehaug, J. E., Skorve, J., Berge, R. K., Strand, E., Bjørndal, B., Nygard, O. K., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100770 · Cited by 20
Liu, Z., Luo, Y., Ren, J., Yang, L., Li, J., Wei, Z., He, Y., Wang, J., Li, R., He, L., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33819 · Cited by 18
“A recent umbrella meta-analysis concluded that among 11 meta-analyses that focused on the association between n-3 PUFAs and prostate cancer, two found an inverse association between them, and one found n-3 PUFA consumption could increase the risk of prostate cancer.9 Our results indicated the null association between…”
BackgroundResultInfluentialDietary Intervention for Preventing Colorectal Cancer: A Practical Guide for Physicians
Kim, S. H., Moon, J. Y., & Lim, Y. J. (2022) · Journal of Cancer Prevention · doi:10.15430/jcp.2022.27.3.139 · Cited by 19
“ized trial with 25,871 participants intaking mixed marine n-3 PUFAs (1 g daily) with vitamin D3 (2,000 IU daily) showed an overall negative outcome but demonstrated a significant reduction in colorectal polyp recurrence in groups with low baseline plasma n-3 PUFA levels or African-Americans [54].”
BackgroundBassuk, S. S., & Manson, J. E. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac172 · Cited by 21
Self-citationEicosapentaenoic acid vs. docosahexaenoic acid for the prevention of cardiovascular disease
Sweeney, T. E., Gaine, S. P., & Michos, E. D. (2023) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000796 · Cited by 18
Marine n‐3 fatty acids and cognitive change among older adults in the VITAL randomized trial
Kang, J. H., Vyas, C. M., Okereke, O. I., Ogata, S., Albert, M. A., Lee, I.-M. M., D’Agostino, D., Buring, J. E., Cook, N. R., Grodstein, F., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12288 · Cited by 18
Self-citationDinu, M., Sofi, F., Lotti, S., Colombini, B., Mattioli, A. V., Catapano, A. L., Casula, M., Baragetti, A., Wong, N. D., Steg, P. G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae184 · Cited by 17
Le, V. T., Knight, S., Watrous, J. D., Najhawan, M., Dao, K., McCubrey, R. O., Bair, T. L., Horne, B. D., May, H. T., Muhlestein, J. B., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1229130 · Cited by 18
“Both VITAL, the largest primary prevention trial (n = 25,871), and ASCEND (n = 15,480 patients with diabetes but no evidence of cardiovascular disease) used mixed (EPA and DHA) marine OM3 PUFAs (1 g/day) compared to placebo (12, 13).”
BackgroundInfluentialMcGee, E. E., Kim, C. H., Wang, M., Spiegelman, D. L., Stover, D. G., Heng, Y. J., Collins, L. C., Baker, G. M., Farvid, M. S., Schedin, P. S., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01316-4 · Cited by 17
Fernández, M. L., Blomquist, S. A., Hallmark, B., & Chilton, F. H. (2021) · Nutrients · doi:10.3390/nu13072154 · Cited by 17
“The VITAL Vitamin D and n-3 3 LC-PUFA Trial consisted of 25,871 men aged over 50 years old and women over 55, including 5106 African Americans who received a daily dose of 460 mg of EPA plus 380 mg of DHA or placebo [22].”
InfluentialXu, B., Xu, Z., Xu, D., & Tan, X. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02342-6 · Cited by 17
“These controversies may be confounded by background dietary consumption of fish, health status, medical treatment of IHD, socioeconomic position, lifestyle, different study populations, and different definitions of CVD and study endpoints [1, 10].”
BackgroundInfluentialLipid‐based regulators of immunity
Johnson, W. T., Dorn, N. C., Ogbonna, D. A., Bottini, N., & Shah, N. J. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10288 · Cited by 16
Metadata
- Authors
- Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., D’Agostino, D., Friedenberg, G., Ridge, C., Bubes, V., Giovannucci, E. L., Willett, W. C., & Buring, J. E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (J.E.M., N.R.C., I-M.L., W.C., S.S.B., S.M., H.G., C.M.A., D.G., T.C., D.D., G.F., C.R., V.B., E.L.G., W.C.W., J.E.B.), and the Departments of Epidemiology (J.E.M., N.R.C., I.-M.L., W.C.W., J.E.B.) and Nutrition (E.L.G., W.C.W.), Harvard T.H. Chan School of Public Health — all in Boston.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 23-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6392053
- OpenAlex
- W2899720772
- Semantic Scholar
- bb3183c85d8686140abdf23d14174712153d2ed2
- Cited by
- 979
- References
- 94
- Citations by year
- 2026: 78 · 2025: 93 · 2024: 98 · 2023: 121 · 2022: 130 · 2021: 136 · 2020: 162 · 2019: 141
- FWCI
- 94.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R0 CA138962)
- National Cancer Institute
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
- Keywords
- omega-3 fatty acids, cardiovascular disease prevention, cancer prevention, primary prevention, cardiovascular events, myocardial infarction, stroke, cancer mortality, coronary revascularization, dietary supplementation, cardiovascular risk reduction, cancer risk reduction, older adults, Black participants, cancer risk factors
- MeSH terms
- Aged, Cardiovascular Diseases, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms, Fatty Acids, Omega-3, Incidence, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
